Bio-Works Technologies AB
The answer first
Does Bio-Works Technologies beat the market?
Yes, Bio-Works Technologies has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 15% of Nordic stocks
- Quality41
- Value11
- Trend41
No. 150 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Bio-Works Technologies keeps must grow about 32% a year for 10 years.
Max for seven days
Follow Bio-Works Technologies with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 17 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Bio-Works Technologies
Your first answer is free, no account needed.
Do you own Bio-Works Technologies, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Bio-Works Technologies and a few more. Free, no card.
Super Stock+45.1%In short
- Bio-Works Technologies has risen 21.3% over the past year, including dividends.
- Overall, Bio-Works Technologies ranks better than 15% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 97.2%. The price is 89.8% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 15% of Nordic stocks.
No. 150 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 144 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.01
- Asset turnoverSales divided by everything the company owns1.17
- Return on equityProfit divided by equity−9.1%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 129 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity7.1
- P/SPrice divided by sales3.9
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flow87.3
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 83 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−14.4%
- 6 months−28.5%
- 9 months−2.3%
- 12 months+21.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Bio-Works Technologies
Bio-Works Technologies AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 32 employees.
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chromatography (IMAC) resin, size exclusion chromatography (SEC) resins, HTPD formats, screening kits, and desalting columns; and WorkBeads chromatography resins. Its products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications.


See the full analysis of Bio-Works Technologies.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card